Patient-derived xenografts (PDX) indeed refer to patient-derived tumor tissue that is transplanted into immunodeficient animals, typically mice, for preclinical research purposes. Alfa Cytology provides customized PDX models for bladder cancer research.
PDX models have been recognized as advanced preclinical oncology drug development models. They are widely used in bladder cancer research and therapeutic development due to their ability to recapitulate the heterogeneity and diversity of bladder cancers more accurately. PDX models can also be propagated by sequential transplantation, thus allowing tumor cells to be expanded and maintained for multiple generations.
Patient-Derived Xenograft (PDX) Model
Transplant
Immunodeficient mouse
Tumor
Human tumor cells
They offer several advantages that enhance preclinical drug efficacy testing and analysis.
Alfa Cytology, a leading preclinical Contract Research Organization (CRO), offers a variety of customization services for PDX mouse models to develop novel bladder cancer therapies. Our expert staff can provide you with comprehensive experimental procedures, health reports and relevant experimental data.
PDX models are increasingly being used to enable the following types of preclinical research for bladder cancer:
Alfa Cytology is dedicated to advancing bladder cancer research through our specialized preclinical CRO services. Our team of highly skilled scientists and experts are ready to collaborate with researchers to accelerate their projects and facilitate the discovery of early diagnosis and treatment solutions for bladder cancer. To learn more about our PDX model development services or to discuss your specific research needs, please contact us.
Reference
Alfa Cytology is dedicated to drug development and preclinical services for bladder cancer.